自身抗体状态与早期类风湿关节炎患者一线甲氨蝶呤早期治疗反应无关
从国际观察性数据库(METEOR)选取初治即用甲氨蝶呤的类风湿关节炎患者,按自身抗体状态分层,分析3至6个月内达到缓解与良好身体功能的情况。1826例中17%达到DAS缓解,自身抗体阳性与阴性患者相似(17% vs 18%),自身抗体状态与缓解及HAQ<0.5均无关联。
要点
- 自身抗体阳性与阴性患者3至6个月内DAS缓解率相似(17% vs 18%),自身抗体状态与缓解无关联(HR 0.89)。
- 甲氨蝶呤单药或联合治疗分层后,自身抗体状态与缓解的关联均无统计学意义。
- 自身抗体状态与达到HAQ<0.5也无关联(HR 1.05)。
核心结论
- 自身抗体状态与初治即接受甲氨蝶呤的新诊断类风湿关节炎患者的早期缓解无关,提示甲氨蝶呤作为初始治疗策略的疗效不受自身抗体状态影响。
研究设计与样本
- 从国际观察性数据库(METEOR)选取初治即用甲氨蝶呤的类风湿关节炎患者,按自身抗体状态分为阳性(RF和/或ACPA阳性)与阴性(RF和ACPA均阴性)两组。
- 采用Cox比例风险回归分析自身抗体状态对3至6个月内达到缓解的影响,共1826例患者数据可分析。
主要发现
- 全部患者中17%(318/1826)达到DAS缓解,自身抗体阳性组为17%(282/1629),阴性组为18%(36/197)。
- 自身抗体阳性与缓解无关联(HR 0.89,95%CI 0.57,1.38)。
- 甲氨蝶呤单药治疗分层HR 0.75(95%CI 0.41,1.37),联合治疗分层HR 0.76(95%CI 0.37,1.54)。
- 全部患者中33%(530/1590)达到良好身体功能(HAQ<0.5),自身抗体阳性与HAQ<0.5无关联(HR 1.05,95%CI 0.71,1.57)。
关键数值与推荐
- DAS缓解:全部患者17%(318/1826),自身抗体阳性17%(282/1629),自身抗体阴性18%(36/197)。
- 自身抗体阳性与DAS缓解的HR 0.89(95%CI 0.57,1.38)。
- 甲氨蝶呤单药分层HR 0.75(95%CI 0.41,1.37),联合治疗分层HR 0.76(95%CI 0.37,1.54)。
- HAQ<0.5:全部患者33%(530/1590),自身抗体阳性与HAQ<0.5的HR 1.05(95%CI 0.71,1.57)。
临床怎么用
- 原文结论指出甲氨蝶呤作为初始治疗策略有效,与自身抗体状态无关,原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In RA, the relationship between autoantibody status and treatment response to MTX remains unclear. We investigated the association between autoantibody status and early remission in newly diagnosed RA patients treated with MTX using real-world data. METHODS: RA-patients initially treated with MTX were selected from an international observational database (METEOR). Patients were stratified into autoantibody-positive (RF- and/or ACPA-positive) or autoantibody negative (RF- and ACPA-negative). The effect of autoantibody status on the chance of achieving remission within 3 to 6 months was analysed using Cox-proportional hazards regression. RESULTS: Data from 1826 RA patients were available for analysis. DAS remission was achieved in 17% (318/1826). This was similar in autoantibody-positive [17% (282/1629)] and -negative patients [18% (36/197)]. Hence, autoantibody positivity was not associated with remission [hazard ratio (HR) 0.89, 95% CI 0.57, 1.38]. Similar findings were found when stratified for MTX monotherapy (HR 0.75, 95% CI 0.41, 1.37) or combination treatment (HR 0.76, 95% CI 0.37, 1.54). Good physical function (HAQ < 0.5) was achieved in 33% (530/1590) of all patients. Autoantibody-positivity was also not associated with HAQ < 0.5 (HR 1.05, 95% CI 0.71, 1.57). CONCLUSION: Autoantibody status is not associated with early remission in newly diagnosed RA-patients receiving MTX. This indicates that MTX is effective as an initial treatment strategy regardless of autoantibody status.
引用
- Dekkers JS, Bergstra SA, Chopra A, et al. Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30204896. doi:10.1093/rheumatology/key263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。